UMC Utrecht in the Netherlands has started recruitment for the Compass Pathways-sponsored phase 3 trial of psilocybin-assisted therapy (PAT) for treatment-resistant depression (TRD). This will be the second phase 3 trial initiated by the biotech company, which recently announced positive results from its initial multi-center trial of PAT for TRD. Besides UMC Utrecht, recruitment is also taking place at the UMCG (Groningen) and the Leiden University Medical Center.
Adults suffering from major depressive disorder may apply for the study if they meet the inclusion criteria:
– Having tried at least two different medications for depression (antidepressants) during the current depressive episode, with little or no effect.
– No current diagnosis or history of bipolar disorder, borderline personality disorder, post-traumatic stress disorder, obsessive-compulsive disorder, anorexia nervosa, or a psychiatric disorder that involves psychosis, such as schizophrenia.
– No addiction problems in the past year.
– No admittance to a psychiatric ward in the past six months.
– No presence of a serious medical condition.
– Not currently pregnant and/or breastfeeding.
– No heart problems or severely elevated blood pressure that is not being treated.
For more information, visit the UMC Utrecht website.